Monitor for a prospectus supplement or 8-K announcing an actual ATM draw or shelf takedown — that will be the material catalyst. Until then, the effective shelf creates an overhang that may cap upside. Watch for any secondary offering pricing below current market levels.
Price Chart
Executive Summary
The SEC declared Plus Therapeutics' Form S-3 shelf registration (File No. 333-296411) effective on June 5, 2026. This shelf, covering common stock, preferred stock, debt securities, warrants, and units, includes an at-the-market (ATM) facility with Canaccord Genuity. The effectiveness opens the door for potential future capital raises, creating an ongoing dilution overhang for the company's $37M market cap stock.
Key Facts
- EFFECT notice for S-3 shelf registration (File No. 333-296411) declared effective by SEC on June 5, 2026.
- Shelf covers common stock, preferred stock, debt securities, warrants, and units with an unspecified maximum aggregate offering amount.
- Original S-3/A included an Equity Distribution Agreement with Canaccord Genuity LLC for an at-the-market (ATM) common stock facility.
- Company's market cap is approximately $37M, making even moderate ATM draws potentially dilutive.
- Cross-filing: S-1 IPO registration filed 150 days ago suggests the company has been pursuing multiple capital pathways.
Financial Impact
Potential dilution from future ATM sales or shelf takedowns; no specific offering size or pricing disclosed. Company market cap of $37M amplifies dilution risk from any moderate raise.
Risk Factors
- ATM equity sales could dilute existing shareholders significantly given the small market cap.
- Combined with prior S-1 IPO registration, multiple capital pathways suggest ongoing cash needs.
- No revenue or cash runway details in the EFFECT filing — unknowns about the urgency of capital raising.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001913 |
| Document: 9999999995-26-001913-index.html | 9999999995-26-001913 |
| Document: 9999999995-26-001913.txt | 9999999995-26-001913 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 14w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 17w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 23w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 26w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 27w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers